Inovio Pharmaceuticals/$INO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inovio Pharmaceuticals
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Ticker
$INO
Sector
Primary listing
Employees
112
Headquarters
Website
INO Metrics
BasicAdvanced
$78M
-
-$1.81
1.76
-
Price and volume
Market cap
$78M
Beta
1.76
52-week high
$2.98
52-week low
$1.07
Average daily volume
1.5M
Financial strength
Current ratio
1.4
Quick ratio
1.34
Long term debt to equity
27.163
Total debt to equity
38.877
Profitability
EBITDA (TTM)
-85.404
Gross margin (TTM)
-82,857.43%
Net profit margin (TTM)
-130,000.00%
Operating margin (TTM)
-132,958.81%
Management effectiveness
Return on assets (TTM)
-57.88%
Return on equity (TTM)
-183.47%
Valuation
Price to revenue (TTM)
811.199
Price to book
3.24
Price to tangible book (TTM)
3.24
Price to free cash flow (TTM)
-0.596
Free cash flow yield (TTM)
-167.82%
Free cash flow per share (TTM)
-1.896
Growth
Revenue change (TTM)
-69.99%
Earnings per share change (TTM)
-54.12%
3-year revenue growth (CAGR)
-81.47%
10-year revenue growth (CAGR)
-47.44%
3-year earnings per share growth (CAGR)
-49.50%
10-year earnings per share growth (CAGR)
-10.09%
What the Analysts think about INO
Analyst ratings (Buy, Hold, Sell) for Inovio Pharmaceuticals stock.
INO Financial Performance
Revenues and expenses
INO Earnings Performance
Company profitability
INO News
AllArticlesVideos
INOVIO DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - INO
Newsfile Corp·3 days ago
INOVIO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - INO
Newsfile Corp·5 days ago
INO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026
Newsfile Corp·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals (INO) has a market cap of $78M as of April 05, 2026.
What is the P/E ratio for Inovio Pharmaceuticals stock?
The price to earnings (P/E) ratio for Inovio Pharmaceuticals (INO) stock is 0 as of April 05, 2026.
Does Inovio Pharmaceuticals stock pay dividends?
No, Inovio Pharmaceuticals (INO) stock does not pay dividends to its shareholders as of April 05, 2026.
When is the next Inovio Pharmaceuticals dividend payment date?
Inovio Pharmaceuticals (INO) stock does not pay dividends to its shareholders.
What is the beta indicator for Inovio Pharmaceuticals?
Inovio Pharmaceuticals (INO) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.